About Biomea Fusion, Inc.

Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity. It’s lead clinical program’s drug candidates are COVALENT-111 and COVALENT-112, which has completed Phase II clinical trials of icovamenib for the treatment of Type 1 and Type 2 diabetes; COVALENT-211, which is in Phase II clinical trial of icovamenib for treating insulin-deficient type 2 diabetes; and COVALENT-212, which is in Phase II clinical trial of icovamenib for the treatment of type 2 diabetes. The company is also developing BMF-650, which is in Phase I glucagon-like peptide-131 clinical trial for the treatment of obesity. The company was incorporated in 2017 and is headquartered in San Carlos, California.

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Employees: 37
Price: $1.44
Previous close: $1.44
Market capitalization: $104.11M
Volume: 9,301,263
P/E ratio: -2.90
52-week low: $0.87
52-week high: $2.99

Additional performance and financial-statement views load in the interactive application.

Market information is provided for research and visualization and is not investment advice.